Fed. Circ. Grants Last-Minute Pause Of ITC’s Botox Rival Ban


By Tiffany Hu ยท February 16, 2021, 9:44 PM EST

South Korean-based Daewoong Pharmaceuticals can keep its low-cost version of Allergan’s Botox treatment on the market while the Federal Circuit considers whether it should pause the U.S. International Trade Commission’s import…

To view the full article, register now.

Source link